Journal of Clinical Medicine Research, ISSN 1918-3003 print, 1918-3011 online, Open Access
Article copyright, the authors; Journal compilation copyright, J Clin Med Res and Elmer Press Inc
Journal website http://www.jocmr.org

Original Article

Volume 11, Number 6, June 2019, pages 407-414


The Effect of the New Eighth Edition Breast Cancer Staging System on 100 Consecutive Patients

Figures

Figure 1.
Figure 1. Distribution of the seventh edition anatomic stage, early eighth edition prognostic stage, and current eighth edition prognostic stage among breast cancer patients (n = 100).
Figure 2.
Figure 2. Stage changes in the seventh edition vs. current eighth edition of breast cancer prognostic stage (n = 100).
Figure 3.
Figure 3. Stage changes in the seventh edition vs. early eighth edition of breast cancer prognostic stage (n = 100).
Figure 4.
Figure 4. Stage changes in early eighth edition vs. current eighth edition of breast cancer prognostic stage (n = 100).
Figure 5.
Figure 5. (a) Stage changes across histologic subtypes (the seventh vs. early eighth edition). (b) Stage changes across histologic subtypes (the seventh vs. current eighth edition).
Figure 6.
Figure 6. Distribution of stages across histologic subtypes in current eighth edition.

Tables

Table 1. Demographic and Pathological Characteristics of Studied Breast Cancer Patients (N = 100)
 
CharacteristicN% of cohort
aTumor size grade, nodal status grade, and metastases grade are used for anatomic seventh edition staging of breast cancer tumors.
Age at diagnosis
  35 - 501212%
  > 508888%
Ethnicity
  White9090%
  Black55%
  Asian Indian11%
  Other33%
  N/A11%
Tumor size gradea
  T17070%
  T22424%
  T366%
Nodal status gradea
  N07979%
  N11414%
  N1mi33%
  N233%
  N311%
Metastases gradea
  M09999%
  M111%
Histological grade
  G12020%
  G25252%
  G32828%

 

Table 2. Pathological Classification and Biomarker Status of Studied Breast Cancer Patients (N = 100)
 
CharacteristicN% of cohort
ER: estrogen receptor; PR: progesterone receptor; HER2: human epidermal growth factor receptor-2.
Histology
  Ductal8282%
  Lobular1616%
  Other22%
ER status
  Positive8787%
  Negative1313%
PR status
  Positive7070%
  Negative3030%
HER2 status
  Positive1414%
  Negative8686%
Ki67
  Positive (< 10%)3232%
  Intermediate (10-20%)1010%
  Negative (≥ 20%)4040%
  N/A1818%
Oncotype Dx score
  Low-risk (< 18)2525%
  Intermediate (18 - 30)1515%
  High-risk (≥ 31)11%
  Test not performed4242%
  N/A1717%